by Eric Christianson | Jul 11, 2021 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Ivermectin and hydroxychloroquine have been purported as potential COVID treatments. We break down where these drugs stand in regards to those claims. The NIH COVID-19 Treatment Guidelines Panel have recommended against any use of chloroquine or hydroxychloroquine...
by Eric Christianson | Jul 7, 2021 | Medication and Disease State Clinical Pearls For Pharmacists, Respiratory Medication and Disease State Clinical Pearls
In this article, we’d like to share some of the most common dextromethorphan clinical pearls that you should be aware of. Dextromethorphan (DXM) is an over-the-counter medication often found in many of the Robitussin products, among others. It is approved...
by Eric Christianson | Jun 30, 2021 | Educational Case Studies For Pharmacists, Infectious Disease and Oncology Case Studies
An 89-year-old female has a history of frequent UTIs. She has been taking ciprofloxacin for UTI prophylaxis at 250 mg once daily for about 1 year. She has not had a UTI since starting on the ciprofloxacin. She takes it in the morning with her breakfast. She has a...
by Eric Christianson | Jun 27, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
In this article, we take a look at the Alpha-2 Adrenergic Agonists. In comparing Alpha-2 Adrenergic Agonists, we will primarily look at dosing, adverse effects, and notable indications. Clonidine is FDA-approved for attention deficit hyperactivity disorder (ADHD),...
by Eric Christianson | Jun 23, 2021 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
With insulin products continually coming to market, it can be challenging to stay current with the new information. Here is a brief overview of newly approved insulin products in the last few years, some highlights that might make them unique, and how to switch...
